Reviewer’s report

Title: Interferon Alpha-2a Treatment for Refractory Behcet Uveitis in Korean Patients

Version: 0 Date: 21 Dec 2017

Reviewer: Ariel Schlaen

Reviewer’s report:

This version of the manuscript was improved from the former. In spite of this fact, there are some issues that should be addressed:

No statistical analysis was done to compare the mean number of recurrences before and during the treatment, as well as the mean logMAR BCVA before treatment and at the final follow up. The use of a non parametric test is needed in order to determine the statistical significance of the difference between the means and to support the conclusions.

This test must be described in Methods.

In page 6, line 49, references are needed to support the use of anti TNF, and anti IL drugs in the treatment of Ocular Behcet.

In page 8, line 16, the sentence "There was no patient who could discontinue IFNα2a therapy in this study" is not clear. Please clarify

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal